Clinical Trials in Texas

Showing 2061-2080 of 7,265 trials

Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis

NCT01384630

This is a 73-day phase II, open label trial of the true human monoclonal antibody RA-18C3 in subjects with moderate to severe plaque psoriasis. Ten (10) subjects will receive 200 mg of RA-18C3 via subcutaneous injection. Subjects will receive injections at Days 0, 21, and 42 for a total of 3 injections. Study drug will be administered under close observation in a facility equipped to handle medical emergencies. Subjects will not be discharged from the facility until at least 1 hour following the end of the injection or 1 hour after their vital signs have stabilized. Safety will be assessed by pre- and post-treatment serial measurements of vital signs, clinical laboratory assessments, and the recording of adverse clinical events.

Psoriasis

Janssen Research & Development, LLC8 participantsStarted Sep 2011

Owensboro, Kentucky, United States • Ann Arbor, Michigan, United States • Austin, Texas, United States

COMPLETEDNA55 miles

Safety and Efficacy of the SurVeil™ Drug-Coated Balloon

NCT03241459

To demonstrate the safety and efficacy of the SurVeil Drug-Coated Balloon (DCB) for treatment of subjects with symptomatic peripheral artery disease (PAD) due to stenosis of the femoral and/or popliteal arteries.

Peripheral Arterial DiseasePeripheral Vascular DiseaseArtery Disease, Peripheral+1 more

SurModics, Inc.446 participantsStarted Oct 2017

Birmingham, Alabama, United States • Foley, Alabama, United States • Gilbert, Arizona, United States +60 more locations

Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis

Safety and Efficacy of the SurVeil™ Drug-Coated Balloon

Find Trials by Condition in Texas

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis

Optimal Post Tpa-Iv Monitoring in Ischemic Stroke

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)

Detection and Classification of Cardiac Rhythm and Atrial Fibrillation Using a Finger-worn Ring

Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey

Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting

Envi™-SR Randomized Controlled Trial for Endovascular Treatment of Ischemic Stroke

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL